Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 3
2005 5
2006 5
2007 4
2008 1
2009 1
2010 2
2011 3
2012 2
2013 4
2014 2
2015 3
2016 3
2017 2
2018 2
2019 4
2020 2
2021 5
2022 7
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study.
Nelli F, Fabbri A, Virtuoso A, Giannarelli D, Marrucci E, Fiore C, Giron Berrios JR, Schirripa M, Signorelli C, Chilelli MG, Primi F, Panichi V, Caterini L, Farinelli S, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: ruggeri em. Clin Exp Med. 2024 Jan 20;24(1):13. doi: 10.1007/s10238-023-01263-2. Clin Exp Med. 2024. PMID: 38244147 Free PMC article.
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis.
Signorelli C, Chilelli MG, Giannarelli D, Basso M, Calegari MA, Anghelone A, Lucchetti J, Minelli A, Angotti L, Zurlo IV, Schirripa M, Morelli C, Dell'Aquila E, Cosimati A, Gemma D, Ribelli M, Emiliani A, Corsi DC, Arrivi G, Mazzuca F, Zoratto F, Morandi MG, Santamaria F, Saltarelli R, Ruggeri EM. Signorelli C, et al. Among authors: ruggeri em. Cancers (Basel). 2023 Dec 8;15(24):5758. doi: 10.3390/cancers15245758. Cancers (Basel). 2023. PMID: 38136304 Free PMC article.
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study.
Nelli F, Fabbri A, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Berrios JRG, Scagnoli S, Pisegna S, Cirillo A, Panichi V, Massari A, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: ruggeri em. Front Oncol. 2023 Nov 7;13:1280416. doi: 10.3389/fonc.2023.1280416. eCollection 2023. Front Oncol. 2023. PMID: 38023235 Free PMC article.
Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study.
Nelli F, Signorelli C, Fabbri A, Giannarelli D, Virtuoso A, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Chilelli MG, Primi F, Panichi V, Topini G, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: ruggeri em. Cancers (Basel). 2023 Jul 14;15(14):3625. doi: 10.3390/cancers15143625. Cancers (Basel). 2023. PMID: 37509286 Free PMC article.
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study.
Fabbri A, Nelli F, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Scagnoli S, Pisegna S, Alesini D, Sini V, Orlandi A, Fabi A, Piacentini F, Moscetti L, D'Auria G, Gamucci T, Mazzotta M, Pizzuti L, Vici P, Cretella E, Scavina P, La Cesa A, Persano M, Atzori F, Ruggeri EM. Fabbri A, et al. Among authors: ruggeri em. Front Oncol. 2023 Jun 27;13:1177681. doi: 10.3389/fonc.2023.1177681. eCollection 2023. Front Oncol. 2023. PMID: 37441419 Free PMC article.
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.
Nelli F, Giannarelli D, Fabbri A, Virtuoso A, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Signorelli C, Chilelli MG, Primi F, Panichi V, Topini G, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: ruggeri em. Cancer Immunol Immunother. 2023 Oct;72(10):3217-3228. doi: 10.1007/s00262-023-03489-1. Epub 2023 Jul 10. Cancer Immunol Immunother. 2023. PMID: 37428196 Free PMC article.
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study.
Signorelli C, Calegari MA, Basso M, Anghelone A, Lucchetti J, Minelli A, Angotti L, Zurlo IV, Schirripa M, Chilelli MG, Morelli C, Dell'Aquila E, Cosimati A, Gemma D, Ribelli M, Emiliani A, Corsi DC, Arrivi G, Mazzuca F, Zoratto F, Morandi MG, Santamaria F, Saltarelli R, Ruggeri EM. Signorelli C, et al. Among authors: ruggeri em. Curr Oncol. 2023 Jun 4;30(6):5456-5469. doi: 10.3390/curroncol30060413. Curr Oncol. 2023. PMID: 37366896 Free PMC article.
66 results